Restricted accessResearch articleFirst published online 2023-07
Effect of Treatment with Topical Azithromycin or Oral Doxycycline on Tear Film Thickness in Patients with Meibomian Gland Dysfunction: A Randomized Controlled Trial
This prospective, randomized, observer-masked, parallel-group study aimed to compare the effect of topical azithromycin and oral doxycycline on tear film thickness (TFT) and signs and symptoms of ocular surface disease (OSD) in patients with meibomian gland dysfunction (MGD).
Methods:
Patients were randomized to either receive topical azithromycin or oral doxycycline. After a baseline visit, three follow-up visits at intervals of 2 weeks were scheduled. Main outcome of the study was change in TFT as measured with ultrahigh resolution optical coherence tomography.
Results:
Twenty patients were included in the analysis. TFT significantly increased in both groups (P = 0.028 vs. baseline) with no difference between the groups (P = 0.096). As secondary outcomes, ocular surface disease index (OSDI) score and composite signs of OSD significantly decreased in both groups (P = 0.023 for OSDI and P = 0.016 for OSD signs vs. baseline). While eye-related adverse events (AEs) occurred more frequently in the azithromycin group, systemic AEs were more common in the doxycycline group.
Conclusions:
Both treatments improved signs and symptoms of OSD in patients with MGD with no difference between the groups. Due to the higher frequency of systemic side effects of doxycycline, azithromycin eye drops seem to be an alternative with comparable efficacy. Clinical Trial Registration number: NCT03162497.
Get full access to this article
View all access options for this article.
References
1.
SchaumbergDA, NicholsJJ, PapasEB, et al.The international workshop on meibomian gland dysfunction: Report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci, 2011; 52(4):1994–2005; doi: 10.1167/iovs.10-6997e
2.
ThodeAR, LatkanyRA. Current and emerging therapeutic strategies for the treatment of meibomian gland dysfunction (MGD). Drugs, 2015; 75(11):1177–1185; doi: 10.1007/s40265-015-0432-8
3.
NelsonJD, ShimazakiJ, Benitez-del-CastilloJM, et al.The international workshop on meibomian gland dysfunction: Report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci, 2011; 52(4):1930–1937; doi: 10.1167/iovs.10-6997b
4.
NicholsKK, FoulksGN, BronAJ, et al.The international workshop on meibomian gland dysfunction: Executive summary. Invest Ophthalmol Vis Sci, 2011; 52(4):1922–1929; doi: 10.1167/iovs.10-6997a
5.
TomlinsonA, BronAJ, KorbDR, et al.The international workshop on meibomian gland dysfunction: Report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci, 2011; 52(4):2006–2049; doi: 10.1167/iovs.10-6997f
6.
VerjeeMA, BrissetteAR, StarrCE. Dry eye disease: Early recognition with guidance on management and treatment for primary care family physicians. Ophthalmol Ther, 2020; 9(4):877–888; doi: 10.1007/s40123-020-00308-z
7.
SongH, ZhangM, HuX, et al.Correlation analysis of ocular symptoms and signs in patients with dry eye. J Ophthalmol, 2017; 2017:1247138; doi: 10.1155/2017/1247138
8.
FengaC, AragonaP, Di NolaC, et al.Comparison of ocular surface disease index and tear osmolarity as markers of ocular surface dysfunction in video terminal display workers. Am J Ophthalmol, 2014; 158(1):41–48.e2; doi: 10.1016/j.ajo.2014.03.007
9.
SchmidlD, SchlatterA, ChuaJ, et al.Novel approaches for imaging-based diagnosis of ocular surface disease. Diagnostics (Basel), 2020; 10(8):589; doi: 10.3390/diagnostics10080589
10.
HanSB, LiuYC, Mohamed-NoriegaK, et al.Objective imaging diagnostics for dry eye disease. J Ophthalmol, 2020; 2020:3509064; doi: 10.1155/2020/3509064
11.
GarhöferG, Dos SantosVA, StegmannH, et al.The association between tear film thickness as measured with OCT and symptoms and signs of dry eye disease: A pooled analysis of 6 clinical trials. J Clin Med, 2020; 9(11):3791; doi: 10.3390/jcm9113791
12.
SchmidlD, WitkowskaKJ, KayaS, et al.The association between subjective and objective parameters for the assessment of dry-eye syndrome. Invest Ophthalmol Vis Sci, 2015; 56(3):1467–1472; doi: 10.1167/iovs.14-15814
13.
LiJ, MaJ, HuM, et al.Assessment of tear film lipid layer thickness in patients with Meibomian gland dysfunction at different ages. BMC Ophthalmol, 2020; 20(1):394; doi: 10.1186/s12886-020-01667-8
14.
HwangH, JeonHJ, YowKC, et al.Image-based quantitative analysis of tear film lipid layer thickness for meibomian gland evaluation. Biomed Eng Online, 2017; 16(1):135; doi: 10.1186/s12938-017-0426-8
15.
EomY, LeeJS, KangSY, et al.Correlation between quantitative measurements of tear film lipid layer thickness and meibomian gland loss in patients with obstructive meibomian gland dysfunction and normal controls. Am J Ophthalmol, 2013; 155(6):1104–1110.e2; doi: 10.1016/j.ajo.2013.01.008
16.
De BenedettiG, VaianoAS. Oral azithromycin and oral doxycycline for the treatment of Meibomian gland dysfunction: A 9-month comparative case series. Indian J Ophthalmol, 2019; 67(4):464–471; doi: 10.4103/ijo.IJO_1244_17
17.
YooSE, LeeDC, ChangMH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol, 2005; 19(4):258–263; doi: 10.3341/kjo.2005.19.4.258
18.
OnghansengN, NgSM, HalimMS, et al.Oral antibiotics for chronic blepharitis. Cochrane Database Syst Rev, 2021; 6(6):Cd013697; doi: 10.1002/14651858.CD013697.pub2
19.
SatitpitakulV, RatanawongphaibulK, KasetsuwanN, et al.Efficacy of azithromycin 1.5% eyedrops vs oral doxycycline in meibomian gland dysfunction: A randomized trial. Graefes Arch Clin Exp Ophthalmol, 2019; 257(6):1289–1294; doi: 10.1007/s00417-019-04322-1
20.
FoulksGN, BorchmanD, YappertM, et al.Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: A comparative clinical and spectroscopic pilot study. Cornea, 2013; 32(1):44–53; doi: 10.1097/ICO.0b013e318254205f
21.
GeerlingG, TauberJ, BaudouinC, et al.The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci, 2011; 52(4):2050–2064; doi: 10.1167/iovs.10-6997g
22.
SchiffmanRM, ChristiansonMD, JacobsenG, et al.Reliability and validity of the ocular surface disease index. Arch Ophthalmol, 2000; 118(5):615–621; doi: 10.1001/archopht.118.5.615
23.
WerkmeisterRM, AlexA, KayaS, et al.Measurement of tear film thickness using ultrahigh-resolution optical coherence tomography. Invest Ophthalmol Vis Sci, 2013; 54(8):5578–5583; doi: 10.1167/iovs.13-11920
24.
BlackieCA, SolomonJD, ScaffidiRC, et al.The relationship between dry eye symptoms and lipid layer thickness. Cornea, 2009; 28(7):789–794; doi: 10.1097/ICO.0b013e318191b870
25.
KashkouliMB, FazelAJ, KiavashV, et al.Oral azithromycin versus doxycycline in meibomian gland dysfunction: A randomised double-masked open-label clinical trial. Br J Ophthalmol, 2015; 99(2):199–204; doi: 10.1136/bjophthalmol-2014-305410
26.
WolffsohnJS, AritaR, ChalmersR, et al.TFOS DEWS II diagnostic methodology report. Ocul Surf, 2017; 15(3):539–574; doi: 10.1016/j.jtos.2017.05.001
27.
LempMA.Report of the national eye institute/industry workshop on clinical trials in dry eyes. CLAO J, 1995; 21(4):221–232.
28.
VersuraP, CamposEC. TearLab® Osmolarity System for diagnosing dry eye. Expert Rev Mol Diagn, 2013; 13(2):119–129; doi: 10.1586/erm.12.142
29.
AronowiczJD, ShineWE, OralD, et al.Short term oral minocycline treatment of meibomianitis. Br J Ophthalmol, 2006; 90(7):856–860; doi: 10.1136/bjo.2006.091579
30.
KallabM, SzegediS, HommerN, et al.Topical low dose preservative-free hydrocortisone reduces signs and symptoms in patients with chronic dry eye: A randomized clinical trial. Adv Ther, 2020; 37(1):329–341; doi: 10.1007/s12325-019-01137-8
31.
AritaR, FukuokaS. Efficacy of azithromycin eyedrops for individuals with meibomian gland dysfunction-associated posterior blepharitis. Eye Contact Lens, 2021; 47(1):54–59; doi: 10.1097/icl.0000000000000729
32.
OlsonMC, KorbDR, GreinerJV. Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens, 2003; 29(2):96–99; doi: 10.1097/01.Icl.0000060998.20142.8d
33.
AritaR, FukuokaS, MizoguchiT, et al.Multicenter study of intense pulsed light for patients with refractory aqueous-deficient dry eye accompanied by mild meibomian gland dysfunction. J Clin Med, 2020; 9(11):3467; doi: 10.3390/jcm9113467
34.
KayaS, SchmidlD, SchmettererL, et al.Effect of hyaluronic acid on tear film thickness as assessed with ultra-high resolution optical coherence tomography. Acta Ophthalmol, 2015; 93(5):439–443; doi: 10.1111/aos.12647
35.
ChanTC, YeC, NgPK, et al.Change in tear film lipid layer thickness, corneal thickness, volume and topography after superficial cauterization for conjunctivochalasis. Sci Rep, 2015; 5:12239; doi: 10.1038/srep12239
36.
CilogluE, ÖzcanAA, IncekalanT, et al.The role of topical azithromycin in the treatment of meibomian gland dysfunction. Cornea, 2020; 39(3):321–324; doi: 10.1097/ico.0000000000002233
37.
Zhang-NunesS, GuoS, LeeD, et al.Safety and efficacy of an augmented intense pulse light protocol for dry eye syndrome and blepharitis. Photobiomodul Photomed Laser Surg, 2021; 39(3):178–184; doi: 10.1089/photob.2020.4913
38.
CwiklikL.Tear film lipid layer: A molecular level view. Biochim Biophys Acta, 2016; 1858(10):2421–2430; doi: 10.1016/j.bbamem.2016.02.020
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
